SOLARIMS
Solriamfetol
MS, type not stated · phase 2 · 46 participants
Main results due Dec 2026
Symptoms
Assembled by software from public sources.
Solriamfetol
MS, type not stated · phase 2 · 46 participants
Main results due Dec 2026
Symptoms
Metformin
MS, type not stated · phase 2 · 30 participants
Main results due Jan 2027
Relapses
Ublituximab
Relapsing MS · phase 3 · 800 participants
Main results due Jan 2027
Relapses
Acetylcysteine
Progressive MS · phase 2 · 98 participants
Main results due Feb 2027
Repair
Metformin
Progressive MS · phase 2 · 120 participants
Main results due Feb 2027
Progression
Frexalimab
Relapsing MS · phase 3 · 1,655 participants
Main results due May 2027
Relapses
Cladribine
Relapsing and progressive MS · phase 3 · 188 participants
Main results due Jun 2027
Repair
Stopping or reducing treatment
Progressive MS · phase 3 · 250 participants
Main results due Jul 2027
Progression
Cell therapies and tolerisation
Progressive MS · phase 2 · 45 participants
Main results due Oct 2027
Progression
Natalizumab
Early MS · phase 2 · 40 participants
Main results due Oct 2027
Prevention
| Area | Due | Trial | Tests | Type of MS | Phase | Participants |
|---|---|---|---|---|---|---|
| 2027 | ||||||
| Relapses | Dec 2027 | TOTEM-RRMS | Testosterone | Relapsing MS | phase 2 | 40 |
| Progression | Dec 2027 | ChariotMS | Cladribine | Progressive MS | phase 3 | 204 |
| 2028 | ||||||
| Symptoms | Jan 2028 | Arbaclofen, phase 3 | Arbaclofen | MS, type not stated | phase 3 | 442 |
| Symptoms | Jan 2028 | Neuromodulation device, phase 2 | Neuromodulation device | Relapsing and progressive MS | phase 2 | 170 |
| Progression | Mar 2028 | FREVIVA | Frexalimab | Relapsing and progressive MS | phase 3 | 943 |
| 2029 | ||||||
| Relapses | Jul 2029 | Remibrutinib, phase 3 | Remibrutinib | Relapsing MS | phase 3 | 400 |
| 2030 | ||||||
| Relapses | Jan 2030 | Ublituximab, phase 3 | Ublituximab | Relapsing MS | phase 3 | 240 |
| Progression | Jun 2030 | Orelabrutinib, phase 3 | Orelabrutinib | Relapsing and progressive MS | phase 3 | 990 |
| Progression | Jun 2030 | Orelabrutinib, phase 3 | Orelabrutinib | Progressive MS | phase 3 | 705 |
| Relapses | Aug 2030 | BEAT-MS | Stem cell transplantation | Relapsing and progressive MS | phase 3 | 156 |
| Progression | Dec 2030 | REMASTER | Remibrutinib | Progressive MS | phase 3 | 1,275 |
| 2031 | ||||||
| Relapses | Jun 2031 | DESIRE MS | Stopping or reducing treatment | Relapsing and progressive MS | phase 3 | 250 |